Cellebrite Thomas Hogan Sells 103K Shares: Investor Outlook
Cellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
Target date funds adjust asset allocations over time toward a chosen retirement year, simplifying diversification and rebalancing for many savers.
19,808 articlesCellebrite's CEO moved a sizable stake, selling 103,000 shares for about $1.6 million. This article breaks down what ...
Bitcoin climbed through the 65,000 level, signaling fresh momentum. Traders weigh whether the rally will last or fade...
JPMorgan CEO Jamie Dimon outlined a plan to fix a looming shipbuilding labor gap, arguing 300,000 skilled trades work...
A year after XRP surged to $3.65, ripple (xrp) peaked $3.65 remains a milestone. Today, the token is far lower as reg...
Memory chips power today’s data centers, AI accelerators, and personal devices. This guide breaks down the case for S...
Two Vanguard long-duration bond ETFs sit at the center of many fixed-income decisions: VGLT (Long-Term Treasury) and ...
Compass widens its Code of Ethics complaints against Zillow across multiple states and MLSs, signaling a new phase in...
Novartis faces a nuanced path in 2026, balancing new therapies with cost discipline. This guide breaks down the key d...
A new industry report shows on-time flight arrivals at their worst since 2014, pushed by higher fuel costs and volati...
Microsoft is recalibrating its internal AI tools as costs climb, signaling a broader shift in how AI is priced into b...
Analysts debate Cardano's valuation as ADA weakens and on-chain metrics lag, challenging bulls and funds alike. The d...
The Nasdaq plans a 15‑session fast-track entry for AI leaders into the Nasdaq 100, while the S&P considers shortening...